

Contents lists available at ScienceDirect

## Molecular and Cellular Endocrinology



journal homepage: www.elsevier.com/locate/mce

## 5,7,3',4',5'-pentamethoxyflavone (PMF) exhibits anti-obesity and neuroprotective effects in an obese zebrafish model

Muhammad Sufyan Vohra<sup>a</sup>, Bilal Ahmad<sup>b,1</sup>, Emerald R. Taylor<sup>c</sup>, Khaled Benchoula<sup>a</sup>, Isabel Lim Fong<sup>d,e</sup>, Ishwar S. Parhar<sup>f</sup>, Satoshi Ogawa<sup>f</sup>, Christopher J. Serpell<sup>g,\*</sup>, Eng Hwa Wong<sup>a,h,\*\*</sup>

<sup>a</sup> School of Medicine, Faculty of Health and Medical Sciences, Taylor's University Lakeside Campus, 47500, Subang Jaya, Selangor Darul Ehsan, Malaysia

<sup>b</sup> School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University Lakeside Campus, 47500, Subang Jaya, Selangor Darul Ehsan, Malaysia

<sup>c</sup> School of Chemistry and Forensic Science, Ingram Building, University of Kent, Kent, Canterbury, CT2 7NH, United Kingdom

<sup>d</sup> Department of Paraclinical Sciences, Faculty of Medicine and Health Sciences, 94300, Kota Samarahan, Malaysia

<sup>e</sup> Universiti Malaysia Sarawak, Malaysia

<sup>f</sup> School of Medicine and Health Sciences, Monash University, Sunway Campus, PJ 46150, Selangor, Malaysia

<sup>8</sup> Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1 1AX, United

Kingdom

Keywords:

Obesity

Flavones

Anti-adipogenic

Neuroprotective effects

Anti-oxidative

h Digital Health and Medical Advancement Impact Lab, Taylor's University Lakeside Campus, 1, Jalan Taylor's, Subang Jaya, Selangor, 47500, Malaysia

ABSTRACT

## ARTICLE INFO

Obesity is a multi-chronic illness characterized by superfluous fat accumulation, contributing to significant metabolic and neurological complications. Current therapeutic approaches have limited efficacy and notable side effects, underscoring an urgent demand for novel, safer alternatives. This study is the first to investigate the antiobesity potential of 5,7,3',4',5' pentamethoxyflavone (PMF) in vivo using a zebrafish model. Our findings demonstrate that PMF administration exerts pronounced anti-obesogenic effects, evidenced by reductions in blood glucose, plasma triglycerides, total cholesterol, hepatic low-density lipoproteins (LDL), and high-density lipoproteins (HDL). Mechanistically, PMF suppressed hepatic adipogenic and lipogenic gene expression while promoting lipid catabolism through activation of peroxisome proliferator-activated receptor-alpha (PPAR-a) and its downstream enzymes, including acyl-CoA oxidase 1 (ACOX1), medium-chain acyl-CoA dehydrogenase (ACADM), and carnitine palmitoyl transferase 1B (CPT-1β). Additionally, PMF markedly mitigated oxidative stress by lowering malondialdehyde (MDA) and nitric oxide (NO) levels, accompanied by increased antioxidant enzyme activities, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione S-transferase (GST). Notably, PMF effectively prevented obesity by suppressing food intake, downregulating orexigenic genes, and enhancing anorexigenic signals. Furthermore, PMF exhibited neuroprotective properties by elevating brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase B2 (TrkB2), revealing a novel link between metabolic and neurological regulation. This study provides pioneering, comprehensive in vivo evidence supporting PMF as a promising therapeutic candidate with dual beneficial roles in metabolic health and neuroprotection.

## 1. Introduction

Obesity is an increasingly widespread disorder, affecting all ages and genders across the globe (Afolabi et al., 2020; Cizza, 2022). The Atlas

report from the World Obesity Federation (WOF) stated that in 2020 approximately 770 million adults globally were adversely affected by obesity (Lobstein et al., 2022). Obesity is caused by a decrease in energy expenditure and/or increased energy intake for a prolonged period,

E-mail addresses: chris.serpell@ucl.ac.uk (C.J. Serpell), EngHwa.Wong@taylors.edu.my (E.H. Wong).

https://doi.org/10.1016/j.mce.2025.112554

Received 14 January 2025; Received in revised form 14 April 2025; Accepted 17 April 2025 Available online 17 April 2025 0303-7207/© 2025 Published by Elsevier B.V.

<sup>\*</sup> Corresponding author.

<sup>\*\*</sup> Corresponding author. School of Medicine, Faculty of Health and Medical Sciences Taylor's University Lakeside CampusDigital Health and Medical Advancement Impact Lab, Taylor's University Lakeside Campus, 1, Jalan Taylor's, Subang Jaya, Selangor, 47500, Malaysia.

<sup>&</sup>lt;sup>1</sup> Current address: Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, Missouri USA.